Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HS-10516 in combination therapy for advanced clear cell renal cell carcinoma
CTR20252573Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10516, lenvatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Hengrui Therapeutics. Started Jul 2025; status: active.
02
Drugs
HS-10516lenvatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20252573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252573.